NCT05317819 - Study of ADI-PEG 20 Versus Placebo in Subjects with High Arginine Level and Unresectable Hepatocellular Carcinoma | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions

Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma

Interventions

DRUG

ADI-PEG20

Treatment for hepatocellular carcinoma

OTHER

Placebo

Treatment for hepatocellular carcinoma

Trial Locations (11)

333

RECRUITING

Chang Gung Medical Foundation-Linkou (CGMF-LK), Taoyuan District

500

RECRUITING

Changhua Christian Hospital (CCH), Changhua

600

RECRUITING

Ditmanson Medical Foundation Chiayi Christian Hospital (CYCH), Chiayi City

613

RECRUITING

Chang Gung Medical Foundation-Chia-Yi (CGMF-CY), Chiayi City

710

RECRUITING

Chi Mei Medical Center (CMMC-YK), Tainan City

736

RECRUITING

Chi Mei Hospital, Liouying (CMMC-LY), Tainan City

807

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH), Kaohsiung City

833

RECRUITING

Chang Gung Medical Foundation-Kaohsiung(CGMF-KS), Kaohsiung City

49000

NOT_YET_RECRUITING

Hue Central Hospital, Huế

100000

NOT_YET_RECRUITING

Bach Mai Hospital, Hanoi

NOT_YET_RECRUITING

K Hospital, Hà Nội